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BACKGROUND: Desmocollin 3 (DSC3), a member of the cadherin superfamily and integral component of desmosomes, is involved in
carcinogenesis. However, the role of DSC3 in colorectal cancer (CRC) has not yet been established.
METHODS: Desmocollin 3 expression in CRC cell lines was analysed by RT–PCR and western blotting. Methylation status of DSC3
was examined by demethylation tests, methylation-specific PCR, and bisulphite sequencing (BS). The regulatory role of p53 was
investigated by transfection.
RESULTS: Desmocollin 3 was downregulated in CRC cells at mRNA and protein levels. Desmocollin 3 expression was restored in five
out of seven cell lines after 5-aza-20-deoxycytidine (DAC) treatment. A heterogeneous methylation pattern was detected by BS in
promoter region and exon 1 of DSC3. Methylation of DSC3 genomic sequences was found in 41% (41 out of 99) of primary CRC,
being associated with poor prognosis (P¼0.002). Transfection of p53 alone or in combination of DAC increased the DSC3
expression. Similarly, treatment with p53 inducer adriamycin alone or in combination with DAC enhanced DSC3 expression.
CONCLUSIONS: DNA methylation contributes to downregulation of DSC3 in CRC cell lines. Methylation status of DSC3 DNA is
a prognostic marker for CRC. P53 appears to have an important role in regulating DSC3 expression.
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Colorectal cancer (CRC) is the third most frequently diagnosed
cancer in men and women in the United States. With 655000
deaths worldwide per year, this cancer type is also the third most
common leading cause of cancer-related death in the western
world (Cunningham et al, 2010). Improved treatment and efficient
surveillance contributed to control the disease; however, the
overall 5-year survival rate of CRC is still poor (Hamilton and
Aaltonen, 2000).
Colorectal cancer arises through multiple genetic changes,
including mutations of APC, TP53, RAS, and RAF (Kouzminova
et al, 2010). However, epigenetic alternations such as DNA
methylation also have an important role through the silencing of
cancer-related genes in CRC (Jones and Baylin, 2007). Cancer cells
often have both a loss of global methylation and a gain of
methylation at the promoter of selected CpG islands, resulting in
the silencing of hundreds of genes (Jones and Baylin, 2002; Issa,
2004). Indeed, DNA methylation has been proven to be a useful
marker of disease risk, progression, and prognosis in various
malignancies including CRC. Recently, a specific DNA methylation
inhibitor 5-aza-20-deoxycytidine (DAC, also called decitabine)
was approved by the FDA for the treatment of the haematologic
malignancy myelodysplastic syndrome in the United States of
America (Lemaire et al, 2008).
P53 is a tumour suppressor protein that acts as a checkpoint in
the cell cycle, either preventing or initiating programmed cell
death (Buckbinder et al, 1995). Loss of normal p53 function occurs
in many human tumours and primarily is caused by mutation or
deletion of the p53 gene (Amaral et al, 2010). Many p53 target
genes have been reported to be important for maintenance of
normal cellular behaviour, and a loss of p53 regulation may cause
abnormal expression of these genes. Interestingly, several targets
of p53 are silenced by DNA methylation (Wales et al, 1995; Suzuki
et al, 2000; Christoph et al, 2006).
Desmosomes represent lateral punctate cell–cell junctions
linked with the intermediate filament apparatus of vertebrate
cells. Members of the desmosomal cadherin family, including
democollins 1–3 (DSCs) and desmogleins 1–4 (DSGs), are found
primarily in epithelial cells where their extracellular domains
constitute the adhesive interface, and together with cytosolic
plaque proteins are required for assembly and maintenance of
desmosome (Garrod et al, 2002). Impaired desmosomal protein
function is associated with multiple diseases (Huber, 2003). One of
the interesting functions of desmosomal proteins related to cancer
is their ability to inhibit cell motility (Tselepis et al, 1998). Indeed,
evidence supporting the involvement of desmosomal proteins
in carcinogenesis is growing. For example, DSG2 was found to
be overexpressed in skin cancer (Kurzen et al, 2003), whereas DSG
3 was upregulated in head and neck cancer and lung cancer
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s(Chung et al, 2004; Chen et al, 2007; Fukuoka et al, 2007). By
contrast, DSC3 was downregulated in breast cancer due to
promoter hypermethylation (Oshiro et al, 2005).
In this study, we analysed the DSC3 expression, investigated the
methylation status of DSC3 genomic sequences, and explored the
role of p53 in the regulation of DSC3 expression in CRC.
MATERIALS AND METHODS
Cell lines and cell culture
Human normal colon cells (CCD-33Co) were purchased from the
American Type Culture Collection (ATCC, Rockville, MD, USA).
Human colon cancer cell lines (HT-29, LoVo, Caco-2, WiDr,
SW480, HCT116, and HRT-18) were purchased from ATCC. CX-2
was obtained as a gift from Dr Antje Siegert (Institute of Pathology,
Charite ´ Berlin). HT-29, SW480, and HCT116 were grown in
Leibovitz 15 medium supplemented with 10% FCS and 1%
glutamine. Caco-2, WiDr, CX-2, and HRT-18 were cultured
in RPMI1640 medium supplemented with 10% (v/v) FCS and 1%
(w/v) glutamine. LoVo was cultured in DMEM medium including
10% (v/v) FCS, 1% (w/v) glutamine, and 4.5% (w/v) glucose.
RNA extraction and real-time RT–PCR
Total RNA was extracted from cells using the Trizol reagent
(Invitrogen, Darmstadt, Germany) according to manufacturer’s
instructions. One microgram of total RNA was incubated with RQ1
RNase-free DNase (Promega, Madison, WI, USA) for 30min at
371C to eliminate genomic DNA contamination. Messenger RNA
was reverse-transcribed by 15 U ThermoScript RT (Invitrogen)
from DNase-treated RNA in the presence of 1  RT buffer, 100mM
DTT, 20U RNase inhibitor, and 10mM dNTPs, using the random
hexamer primers supplied in the kit.
Expression of DSC3 was analysed by real-time PCR. Real-time
PCR was performed in 0.1ml tubes on the Rotor-Gene 6000
(Qiagen, Hilden, Germany) in the presence of the FastStart
Universal SYBR Green Master (Roche, Mannheim, Germany).
Twenty-five nanograms of RNA were used for PCR amplification
with the following primer pairs for DSC3: 50-GAAAGTAGTAG
ACCTGGTACT-30 (forward), 50-ACGCCTGTGCTGGGATGCA-30
(reverse) and for p53: 50-GGTGGTGCCCTATGAGCCG-30 (for-
ward), 50-TCCTCTGTGCGCCGGTCTC-30 (reverse). As an internal
control, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
amplified using the primer pair: 50-TCAAGGGCATCCTGGGCTA
CA-30 (forward) and 50-CCAGCCCCAGCGTCAAAGGT-30 (re-
verse). The relative expression value of DSC3 to GAPDH in each
sample was calculated and compared.
Western blot analysis
Protein from cell lysates was isolated, and 20mg of protein were
used for western blot analysis according to standard protocols.
Monoclonal anti-desmocollin-3 antibody (Acris, Herford, Germany)
was used at a 1:100 dilution. Signal was visualised with peroxidase-
conjugated polyclonal rabbit anti-mouse antibody (1:1000, DAKO,
Hamburg, Germany) and ECL Plus Western Blotting Detection
Reagents (GE Healthcare, Mu ¨nchen, Germany).
Bisulphite modification and methylation-specific PCR
Bisulphite conversion of genomic DNA was carried out using an
EZ DNA Methylation kit (ZYMO Research, Freiburg, Germany).
This process converts unmethylated cytosine to uracil, whereas
methylated cytosine remains unchanged. Methylation-specific PCR
(MSP) was then carried out to determine the methylation status of
DSC3 in colon cancer cell lines and primary colon tumour tissues.
Bisulphite-modified DNA was used as a template for PCR with
primers specific for methylated or unmethylated alleles.
The primer sequences were as follows: 50-GGGTGTGTTAGAGA
TTGTTTTTTT-30 (forward) and 50-AAACAACTTCACTTCTAAAA
CCAAA-30 (reverse) for amplification of unmethylated allele, 50-GT
GCGTTAGAGATCGTTTTTTC-30 (forward) and 50-AAACAACTTC
ACTTCTAAAACCGAA-30 (reverse) for amplification of methyl-
ated allele. PCR conditions were as follows: 941C 1min, 601C4 5s ,
and 721C 45s, for 40 cycles, with initial denaturation at 951C for
15min and final elongation at 721C for 7min. The PCR products
were visualised on a 1.5% (w/v) agarose gel stained with ethidium
bromide.
Bisulphite sequencing
Bisulphite-treated DNA was subjected to PCR amplification. To
determine the methylation pattern of the CpG islands within the
DSC3 promoter and exon 1, two pairs of primers for bisulphite
sequencing (BS) were designed. These primers were specific to the
modified template but did not contain any CpG site in their
sequences, so they could amplify both methylated and unmethyl-
ated sequences. The primer pair BSP-PF (50-TTGGGGTTTTGT
ATTGAGATGTA-30) and BSP-PR (50-AACCTACCCCTCTACTC
CCC-30) were used to amplify the CpG island in the promoter
region with an expected product of 210-bp. The second primer pair
BSP-EF (50-GAGGGTTAGTAGTAGATGTAGGTA-30) and BSP-ER
(50-AACAAAACCTAAAAAAAACCAA-30) were designed to amplify
the CpG island in the region of exon 1 and the size of the product
was 189-bp. Hot Start PCR (PEQLAB, Erlangen, Germany) was
carried out to amplify the CpG island of DSC3 with the following
conditions: 951C 15min, 40 cycles of 951C 1min, 601C 45s, and
721C 45s, with a final extension at 721C for 7min. PCR products
were purified by using a PCR purification kit (ZYMO Research),
and 150ng of purified PCR products were applied for direct
sequencing by capillary electrophoresis (Agowa, Berlin, Germany).
Drug treatment and transient transfection
For demethylation tests, the colon cancer cell lines HT-29,
LoVo, WiDr, SW480, CX-2, HCT116, and HRT-18 were plated
and cultured in 10cm dishes. At 50% confluence, 10mM 5-aza-20-
deoxycytidine (DAC; Sigma Chemical Co., St Louis, MO, USA) was
added to the medium on days 0, 2, and 4. Cells were harvested for
total RNA isolation and RT–PCR analysis. To determine the effect
of p53 on DAC-induced expression of DSC3, CX-2, WiDr, and
HRT-18, cells (1 10
5 cells per well in 12-well plates) were treated
with low dose of DAC (5mM) on days 0 and 2 or without DAC. On
day 3, cells were transfected with wild-type p53 expression vector
(gift from Dr Ying Liu, Oxford University, UK) by using lipo-
fectamin 2000 (Invitrogen) and incubated for another 48h. To
investigate the regulatory role of endogenous p53 on DSC3, CX-2,
WiDr, and HRT-18, cells (1 10
5cells per well in 12-well plates)
were first treated with ADR at different concentrations from 0.1 to
1.0mgml
 1 for 24h before analysis of p53 expression. Then, the
three cell lines were treated with 1mM DAC on days 0 and 1, and
subsequently on day 2, ADR was added to a final concentration of
0.5mgml
 1 and incubated for 24h before harvesting of cells for
analysis of DSC3 expression.
Clinical samples and genomic DNA isolation
In total, 99 tumour specimens (paraffin tissues) from patients with
CRC were included for this study (Table 1). All of these patients
were undergoing surgical operation at the Department of Surgery
of the University Hospital Jena. No adjuvant radiotherapy or
chemotherapy was administered before surgery. The study was
approved by the local ethical committee.
All haematoxylin and eosin (H and E) sections were reviewed by
a pathologist (T Kno ¨sel). Suitable areas for genomic DNA isolation
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swere marked on H and E sections. Genomic DNA was extracted by
using a QIAamp DNA Mini Kit (Qiagen). In order to minimise the
contamination of normal mucosa, manual microdissection was
performed before DNA isolation.
Immunohistochemistry
Immunohistochemistry analyses were performed with tumour
specimen obtained from the 99 patients with primary CRC, for
which methylation status has been investigated. Tissue sections
were dewaxed with xylene and gradually hydrated. Antigen
retrieval was performed by treatment in a pressure cooker for
6min. The monoclonal anti-desmocollin-3 antibody (Acris) used
at a 1:50 dilution was incubated at room temperature for 1h.
Detection took place according to the manufacturer’s instructions
(LSAB 2-kits, DAKO). All slides were read by two pathologists (T
Kno ¨sel and I Petersen) who were blinded to the clinical
information. Immunohistochemistry was scored semiquantita-
tively as negative (score 0), weak (score 1), moderate (score 2),
or strong (score 3) as previously described (Chen et al, 2003). For
statistical evaluation, score 0 was considered as negative, whereas
scores 1, 2, and 3 together were positive.
Statistical analysis
Kaplan–Meier survival curves were constructed for statistical
significance with the log-rank tests. All P-values were calculated
two-sided. Difference was considered statistically significant
when P-value was 0.05 or less. The statistical analysis was
performed by using the software package SPSS 13.0 (SPSS,
Chicago, IL, USA).
RESULTS
Expression analysis of DSC3 in colon cancer cell lines
We performed real-time RT–PCR to analyse the expression of
DSC3 in eight colon cancer cell lines together with one normal
colon cell line CCD-33Co. Compared with CCD-33Co, DSC3 mRNA
expression was found downregulated in seven colon cancer cell
lines, except Caco-2 (Figure 1A). Protein expression was analysed
by western blotting showing decreased expression of DSC3 in
cancer cell lines (Figure 1B).
Restoration of DSC3 mRNA expression by
5-aza-20-deoxycytidine
To explore the epigenetic regulation of DSC3, seven colon cancer
cell lines including HT-29, LoVo, WiDr, SW480, CX-2, HCT116, and
HRT-18 were selected for the demethylation tests. After treatment
with 10mM DAC for 96h, DSC3 mRNA expression was restored in
five (HT-29, LoVo, WiDr, HCT116, and HRT-18) out of seven cell
lines. While in the other two cell lines (SW480 and CX-2), no
restoration of DSC3 expression was detectable (Figures 2A and B).
Analysis of DSC3 methylation status in colon cancer cell
lines
The methylation status of DSC3 was determined by MSP in eight








































Figure 1 DSC3 expression analysis in CRC cell lines. (A) Desmocollin 3
mRNA expression was analysed by real-time RT–PCR showing that
DSC3 was downregulated in seven out of eight cancer cell lines. (B)I n
consistence with mRNA expression, western blotting revealed decreased
DSC3 protein expression in CRC cell lines. Actin was used as loading
control.
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Figure 2 Demethylation tests in CRC cell lines. (A) Semiquantitative
RT–PCR and (B) real-time RT–PCR showed that after treatment with
10mM DAC for 96h, DSC3 mRNA expression was upregulated.
( )¼untreated; (þ)¼treated with DAC.
Table 1 Study cohort
DSC3 (M) DSC3 (U) P
Age
p63 16 (16.2%) 32 (32.3%) 0.113
463 25 (25.3%) 26 (26.3%)
Gender
Male 22 (22.2%) 28 (28.3%) 0.769
Female 23 (23.2%) 26 (26.3%)
Tumour differentiation
G1/2 18 (19.6%) 35 (38%) 0.154
G3 19 (20.7%) 20 (21.7%)
Stage
pT1/2 3 (3%) 12 (12.1%) 0.090
pT3/4 38 (38.4%) 46 (46.5%)
Nodal status
pN0 17 (17.2%) 31 (31.3%) 0.240
pN1/2 24 (24.2%) 27 (27.3%)
Abbreviations: DSC3¼desmocollin-3; M¼methylated; N¼unmethylated.
DSC3 in human colorectal cancer
T Cui et al
1015




















sdesigned in the region around the transcription start site of
the DSC3 gene. Methylation-specific PCR showed that DSC3
DNA was methylated in cell line HT-29, LoVo, WiDr, HCT116,
and HRT-18, but completely unmethylated in cell line SW480 and
CX-2 (Figure 3A). This result was in good agreement with the
demethylation tests. The reliability of the MSP results was verified
by direct DNA sequencing (Figure 3B).
To confirm the MSP results and further evaluate the methylation
status of DSC3 in CRC cell lines, BS was performed for 21 CpG
sites ( 275,  272,  269, -260,  250,  224,  219,  215,  210,
 204,  201,  199,  190,  183,  160,  150,  142,  138,  136,
 132, and  128) of the promoter region. Consistent with results
of our MSP analysis, a high level of methylation was found in
five out of seven cell lines with downregulated DSC3 expression
(HT-29, LoVo, WiDr, HCT116, and HRT-18), except SW480
and CX-2 (Figure 4A). In exon 1, we evaluated the methylation
status of DSC3 DNA in 20 CpG sites (þ60, þ63, þ79, þ81,
þ93, þ103, þ109, þ120, þ123, þ127, þ129, þ147, þ155,
þ162, þ165, þ175, þ178, þ183, þ187, and þ189). Again,
in these five cell lines, DSC3 was highly methylated (Figure 4B).
As expected, in the cell line Caco-2 with endogenous expression of
DSC3, no methylation of DSC3 was detected.
Methylation of DSC3 predicts poor clinical outcome
The specificity of MSP in CRC cell lines encouraged us to analyse
the methylation status of DSC3 DNA in 99 primary colorectal
tumours by using the same primer pairs. Methylation of DSC3
DNA was detected in 41 out of 99 tumours (41.4%). Examples of
MSP analysis in primary tumours are shown in Figure 5.
Methylation of DSC3 DNA was found in 23 out of 39 (59%)
patients who had a survival time o5 years, whereas in patients
with survival time 45 years, only 30% of the patients (18 out
of 60) harboured DSC3 DNA methylation, reaching statistical
significance (P¼0.004; Table 2). When we further analysed the
effect of methylation on clinical outcome by Kaplan–Meier
analysis, we found that tumours with methylated DSC3 DNA were




70 80 90 100 110
980 990 1000 1010
U
HRT-18





Figure 3 Methylation status of DSC3 DNA in CRC cell lines.
(A) Methylation status of DSC3 DNA was detected by MSP in eight
CRC cell lines. The DSC3 promoter region was unmethylated in the
DSC3-positive cell line Caco-2 as well as in two DSC3-negative cell
lines SW480 and CX-2, while in the other five DSC3-negative cell lines,
the promoter of DSC3 was methylated. (B) Sequencing results of MSP.
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Figure 4 Methylation status of CpG sites in (A) promoter region and (B) exon 1 of DSC3. Black square: methylated CpG site; Grey square: partially
methylated CpG site; White square: unmethylated CpG site.
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U M U M U M U M U M U M U M
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Figure 5 Examples of MSP of DSC3 DNA from patients with primary
CRC. M¼methylated product; U¼unmethylated product.
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ssignificantly correlated to a worse clinical outcome than un-
methylated tumours (P¼0.002, Figure 6). However, the methyla-
tion status was not linked to any of clinical–pathological
parameters including age, gender, size of tumour, tumour grading,
and tumour stage in these patients.
We also analysed the DSC3 protein expression in these 99
primary tumours by immunohistochemistry. It turned out that
DSC3 protein expression was neither associated with clinical–
pathological parameters nor patient survival (data not shown).
Effect of p53 on regulating DSC3 mRNA expression
In breast cancer, p53 was reported to be an upstream factor
regulating expression of DSC3 (Oshiro et al, 2003). To investigate
a potential mechanistic link between p53 and DSC3 expression in
colon cancer cells, we selected three cell lines including CX-2
(DSC3-unmethylated, p53-mutant), WiDr (DSC3-methylated,
p53-mutant), and HRT-18 (DSC3-methylated, p53-wild type) for
transfection with a wild-type p53 expression vector. A successful
transfection was confirmed by real-time RT–PCR analysis and
western blotting demonstrating the upregulation of p53 in the
transfected cell lines, compared with parental cells and mock
transfectants (Supplementary Figure S1). Exogenous expression of
p53 alone induced expression of DSC3 in the unmethylated cell
line CX-2, but not in the methylated cell lines WiDr and HRT-18
(Figure 7A). In contrast, transfection of p53 in combination with
DAC treatment resulted in upregulation of DSC3 expression in the
two methylated cell lines (Figures 7B and C). We further analysed
the effect of endogenous p53 on DSC3 expression by treatment of
CX-2, WiDr, and HRT-18 with adriamycin (ADR), an inducer of
endogenous p53 expression. Induction of p53 mRNA expression
was achieved in the three cell lines by ADR modification with
Table 2 Correlation between DSC3 methylation and survival time
(P-value*)
p5 years 45 years P
DSC3 Methylated 23 (23.2%) 18 (18.2%) 0.004
DSC3 Unmethylated 16 (16.2%) 42 (42.4%)
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Figure 6 Methylation of DSC3 DNA predicted clinical outcome in
primary colorectal cancer. Kaplan–Meier curves showed that patients
whose tumours with methylated DSC3 DNA had shorter survival in





















































































































































Figure 7 Transcriptional activation of DSC3 by p53. (A) Induction of DSC3 mRNA expression after transfection of the three colon cancer cell lines
CX-2, WiDr, and HRT-18 with an expression vector encoding wild-type p53 was measured by quantitative RT–PCR. Mock transfectants (empty vector)
were used as control. (B and C) P53-induced DSC3 expression was enhanced after DAC treatment in the cell lines WiDr and HRT-18. Parental cells were
used as control. (D) Induction of DSC3 transcription by ADR, but not DAC, in the cell line CX-2. (E and F) Synergistic effect of combined ADRþDAC
treatment on WiDr and HRT-18 cells, respectively.
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sdifferent concentrations (Supplementary Figure S2A), while
increased expression of p53 was only observed in the cell line
HRT-18 (Figure S2B) but not in the p53-mutant cell lines CX-2 and
WiDr (Supplementary Figure S2B). The DSC3 expression was
analysed by real-time RT–PCR. It turned out that in the
unmethylated cell line CX-2, ADR alone could markedly enhance
the expression of DSC3 (Figure 7D). In contrast, in the methylated
cell lines WiDr and HRT-18, ADR alone could only slightly
upregulate the DSC3 expression. When ADR was combined with
DAC, a synergistic effect on upregulation of DSC3 expression was
observed in WiDr and HRT-18 (Figures 7E and 7F).
DISCUSSION
Desmocollin 3 is a transmembrane glycoprotein and a member of
the cadherin superfamily of calcium-dependent cell–cell adhesion
molecules. Desmocollin 3 was found to be downregulated in breast
and oral cancer, and gene silencing in breast cancer was caused by
promoter hypermethylation (Oshiro et al, 2005). However, so far
little is known about the role of DSC3 in CRC.
In our study, first, we analysed the mRNA expression of DSC3 in
eight colon cancer cell lines and found that the expression of DSC3
was significantly downregulated in seven out of eight cell lines.
Western blot analysis confirmed these results on the protein level.
Next, we explored the mechanism responsible for the down-
regulation of DSC3 expression in CRC. Gene expression is
modulated by genetic and/or epigenetic mechanisms. So far, no
genetic changes including mutation, deletion, and gene rearrange-
ment of DSC3 have been found in cancer, and except for the
detailed description of methylation patterns in breast cancer, no
methylation analysis of DSC3 in any other tumour entity has been
reported. In our study, demethylation of DSC3 by using the
pharmaceutical agent DAC restored the DSC3 expression in seven
CRC cell lines lacking endogenous DSC3 expression. The DSC3
DNA methylation status in the promoter region and exon 1 of the
gene was analysed by BS. In five out of seven cancer cell lines,
DSC3 DNA methylation was detectable in 21 CpG sites of the
promoter region and in 20 CpG sites of exon 1. The methylation
pattern was however heterogeneous with full methylation of DSC3
in cell line HT-29, and incomplete or partial methylation in LoVo,
WiDr, HCT116, and HRT-18. Treatment of SW480 and CX-2 with
DAC failed to restore the expression of DSC3, and BS showed that
DSC3 DNA was not methylated, suggesting that other mechanisms
might be involved in downregulation of DSC3 in these two cell
lines. These results suggest that DNA hypermethylation contributes
to the gene silencing of DSC3 in a multitude of colon cancer cells.
The methylation pattern of DSC3 in cell lines raised the question
about the methylation status of DSC3 in primary CRC. Therefore,
we performed MSP with genomic DNA from 99 tissues of primary
CRC. It turned out that patients with a survival time o5 years
showed higher rate of methylation (56.1%). On the contrary,
patients who had a survival time of 45 years harboured a lower
rate of methylation (30%). Similarly, tumours with methylated
DSC3 DNA were significantly correlated to a worse clinical
outcome in comparison with unmethylated tumours. These
observations indicated that methylation of the promoter region
was significantly associated with poor clinical outcome, and
methylation status of DSC3 may represent a potential prognostic
marker for patients with CRC.
The regulatory mechanisms controlling DSC3 expression are not
fully understood. Desmocollin 3 is a p53 response gene and
addition of wild-type p53 was found to be sufficient to induce
expression of DSC3 in breast cancer (Klus et al, 2001). Thus, it was
of great interest to investigate whether this pathway is also active
in CRC cells. We found that exogenous expression of p53 increased
the DSC3 expression in the cell line harbouring no DSC3 DNA
methylation. In cancer cell lines with methylated DSC3 DNA,
induction of DSC3 expression after transfection of p53 was only
achieved in the presence of the demethylating agent DAC. We
further tested the role of p53 by inducing its endogenous
expression using ADR. Adriamycin (also called doxorubicin) is
an anticancer drug used in treatment of breast, ovarian, bladder,
and gastric cancers. It has been reported that ADR activates p53
expression and induces p53 target genes during damaged DNA
repair (Adachi et al, 2004; Maruyama et al, 2006; Suzuki et al,
2010). We found that induction of endogenous p53 by ADR
markedly enhanced the expression of DSC3 in the cell line CX-2
with unmethylated DSC3 DNA, while only a slight increase in the
expression of DSC3 was detectable in WiDr and HRT-18 cells
revealing methylated DSC3 DNA. However, in these two cell lines,
combined treatment with ADR and DAC induced DSC3 expres-
sion. These results suggest that combining a DNA methyltransfer-
ase inhibitor with drugs that induce p53-dependent growth
inhibition may represent a useful therapeutic approach for the
treatment of CRC. In fact, DAC has been considered as a part of
combination therapy with other anticancer agents to treat ovarian,
breast, prostate, gastric, lung, pancreatic, and colon cancers
through the relief of DNA hypermethylation (Shames et al, 2007).
In summary, DSC3 is downregulated in CRC cell lines by DNA
methylation. This is the first study reporting a detailed methylation
status of DSC3 DNA in CRC cells. Analysis of the methylation
status of DSC3 DNA may be useful to predict clinical outcomes in
patients with primary CRC. Future studies are necessary to
determine the functional role of DSC3 in CRC initiation and
progression.
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